Cargando…
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
RIDR-PI-103 is a novel reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Under high ROS, PI-103 is released in a controlled manner to inhibit PI3K. The efficacy and bioavailability of RIDR-PI-103 in breast cancer remains...
Autores principales: | Mishra, Rosalin, Yuan, Long, Patel, Hima, Karve, Aniruddha S., Zhu, Haizhou, White, Aaron, Alanazi, Samar, Desai, Pankaj, Merino, Edward J., Garrett, Joan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923228/ https://www.ncbi.nlm.nih.gov/pubmed/33669867 http://dx.doi.org/10.3390/ijms22042088 |
Ejemplares similares
-
RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023) -
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021) -
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023) -
Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
por: Rodgers, Samuel J., et al.
Publicado: (2017) -
HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)